Author
Marianne Ostwald
Bio: Marianne Ostwald is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Survival rate & Chronic lymphocytic leukemia. The author has an hindex of 2, co-authored 2 publications receiving 436 citations.
Papers
More filters
••
TL;DR: In this paper, elevated serum thymidine kinase (s-TK) levels predict disease progression in CLL patients with Binet stage A CLL (mean age +/- SD, 587 +/- 85 years).
247 citations
••
TL;DR: The results show that s-beta 2M and s-TK independently predict progression-free survival in patients with CLL and IC, and suggest that these prognostic factors may allow an improved prediction of progression- free survival, particularly in early disease stages.
Abstract: Chronic lymphocytic leukemia (CLL) and immunocytoma (IC) are remarkably heterogeneous with regard to their clinical course. The current staging systems can distinguish prognostic subgroups, but do not seem to predict the risk of disease progression of an individual patient with sufficient accuracy. Given the increase of treatment options for CLL and IC, additional parameters are needed to decide which patients may benefit from early or intensified treatment. It has been shown that two biochemical markers, serum beta 2-microglobulin (s-beta 2M) and serum thymidine kinase (s-TK), might identify CLL and IC patients at high risk of disease progression. Therefore, the prognostic value of these two serum parameters was compared with a panel of several established prognostic factors in a prospective clinical trial. 113 patients with CLL and 41 patients with IC (mean age +/- SD 63.9 +/- 10.7 years) were included. The following parameters were determined: histopathological diagnosis (IC vs. CLL), age, sex, performance status (Karnofsky index), B symptoms, peripheral blood lymphocyte count, platelet count, blood hemoglobin, serum lactate dehydrogenase (s-LDH), s-beta 2M, s-TK, serum creatinine, number of lymph node areas involved, prior therapy, and the time from diagnosis to inclusion in the study. Univariate analyses showed that nine parameters (Karnofsky index, peripheral blood lymphocytosis, platelet count, blood hemoglobin, lymph node areas involved, pretreatment, s-LDH, s-beta 2M, and s-TK) significantly predicted progression-free survival. In a Cox regression model, only four of these parameters provided independent prognostic information on progression-free survival: 1. s-beta 2M, 2. Karnofsky index, 3. platelet count, and 4. s-TK. The results show that s-beta 2M and s-TK independently predict progression-free survival in patients with CLL and IC, and suggest that these prognostic factors may allow an improved prediction of progression-free survival, particularly in early disease stages.
197 citations
Cited by
More filters
••
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
3,028 citations
••
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
2,388 citations
••
University of Cologne1, Heidelberg University2, University of Mainz3, Praxis4, Ludwig Maximilian University of Munich5, Frankston Hospital6, University of Bologna7, Peter MacCallum Cancer Centre8, Medical University of Vienna9, Charles University in Prague10, University of Ulm11, Hoffmann-La Roche12
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
1,758 citations
••
University of Cologne1, Georgetown University2, Institute of Cancer Research3, Vita-Salute San Raffaele University4, Pasteur Institute5, University of Ulm6, University of Texas MD Anderson Cancer Center7, University of Barcelona8, The Feinstein Institute for Medical Research9, Ohio State University10, University of California, Irvine11, Medical University of Łódź12, Peter MacCallum Cancer Centre13, University of California, San Diego14
TL;DR: Recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
940 citations
••
TL;DR: CD38 expression is an independent risk factor that can be used with IgV(H) mutations and clinical stage to select patients with B-CLL with the worst prognoses.
656 citations